Please contact our sales representative to learn more information about this reagents.
Background
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.